REPL

Replimune Group, Inc. - Common Stock (REPL)

About Replimune Group, Inc. - Common Stock (REPL)

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Details

Daily high

$10.09

Daily low

$9.50

Price at open

$9.75

52 Week High

$17.00

52 Week Low

$6.44

Market cap

732.7M

Dividend yield

0.00%

Volume

861,077

Avg. volume

1.4M

P/E ratio

-2.96

Replimune Group, Inc. - Common Stock News